$3.03 Billion is the total value of BRAIDWELL LP's 81 reported holdings in Q1 2023. The portfolio turnover from Q4 2022 to Q1 2023 was - .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| NBIX | New | NEUROCRINE BIOSCIENCES INC | $77,615,496 | – | 766,800 | +100.0% | 2.56% | – |
| HROW | New | HARROW HEALTH INC | $30,735,704 | – | 1,452,538 | +100.0% | 1.01% | – |
| TERN | New | TERNS PHARMACEUTICALS INC | $23,645,131 | – | 1,997,055 | +100.0% | 0.78% | – |
| IMCR | New | IMMUNOCORE HLDGS PLCads | $21,066,878 | – | 426,110 | +100.0% | 0.70% | – |
| New | PARAGON 28 INC | $18,755,185 | – | 1,098,722 | +100.0% | 0.62% | – | |
| BCRX | New | BIOCRYST PHARMACEUTICALS INC | $16,222,418 | – | 1,945,134 | +100.0% | 0.54% | – |
| VIR | New | VIR BIOTECHNOLOGY INC | $14,055,918 | – | 604,036 | +100.0% | 0.46% | – |
| PACB | New | PACIFIC BIOSCIENCES CALIF IN | $12,706,734 | – | 1,097,300 | +100.0% | 0.42% | – |
| New | ARCELLX INC | $10,284,378 | – | 333,800 | +100.0% | 0.34% | – | |
| AXNX | New | AXONICS INC | $9,095,370 | – | 166,704 | +100.0% | 0.30% | – |
| New | MINERALYS THERAPEUTICS INC | $8,617,698 | – | 550,300 | +100.0% | 0.28% | – | |
| ADPT | New | ADAPTIVE BIOTECHNOLOGIES COR | $5,725,822 | – | 648,451 | +100.0% | 0.19% | – |
| New | ILLUMINA INCnote 8/1 | $1,087,736 | – | 11,100,000 | +100.0% | 0.04% | – | |
| New | AVALO THERAPEUTICS INC | $432,695 | – | 247,254 | +100.0% | 0.01% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2023-05-15
Signatures
The EDGAR filing(s) were signed by:
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| GUARDANT HEALTH INC | 4 | Q3 2023 | 6.3% |
| EXACT SCIENCES CORP | 4 | Q3 2023 | 4.4% |
| NOVOCURE LTD | 4 | Q3 2023 | 3.9% |
| NANOSTRING TECHNOLOGIES INC | 4 | Q3 2023 | 4.0% |
| NEVRO CORP | 4 | Q3 2023 | 3.4% |
| BRIDGEBIO PHARMA INC | 4 | Q3 2023 | 3.5% |
| ALPHATEC HLDGS INC | 4 | Q3 2023 | 3.6% |
| GLAUKOS CORP | 4 | Q3 2023 | 3.0% |
| VAXCYTE INC | 4 | Q3 2023 | 2.8% |
| XENON PHARMACEUTICALS INC | 4 | Q3 2023 | 2.5% |
View BRAIDWELL LP's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-15 |
| SC 13G | 2023-02-14 |
| SC 13G | 2023-02-14 |
| SC 13G | 2023-02-14 |
View BRAIDWELL LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.